• Pediatric Infection and Vaccine
• /
• 제10권1호
• /
• pp.71-80
• /
• 2003

Purpose : Four kinds of Haemophilus influenzae type b protein conjugate vaccines, PRPD, PRP-T, PRP-OMP and PRP-CRM197, have been developed, and PRP-T vaccines are currently produced by two manufacturer, $ActHib^{(R)}$ by Aventis and $Hiberix^{TM}$ by GlaxoSmith-Kline Biologicals. The purpose of this study is to evaluate the immunogenicity and safety of $Hiberix^{TM}$ in Korean infants. Methods : Seventy-three healthy infants(43 male infants) were recruited for this study after parental informed consent was obtained. Each infant was vaccinated at 2, 4 and 6 months of age with the study vaccine. At each visit, infants were also immunized with DTaP, trivalent oral polio vaccine and hepatitis B vaccine when indicated. The serum anti-PRP antibody was measured at prevaccination, 2 month later after the 2nd dose, and 1 month later after the 3rd dose by the ELISA method. The local and systemic adverse reactions of vaccination were monitored for 3 consecutive days after each immunization. Immunogenicity of vaccine was evaluated in infants who received all the scheduled immunization and the adverse reactions were evaluated for infants who received at least one dose of the study vaccine. Results : Among seventy three infants, enrolled in this study; sixty three(37 male infants) completed all the scheduled immunizations. The geometric mean titer(GMT) of anti-PRP antibodies at prevaccination was 0.17 ${\mu}g/mL$(95% confidence interval[CI]; 0.13~0.22). The GMT of anti-PRP antibodies increased to 4.14 ${\mu}g/mL$(95% CI; 2.65~6.48) at 2 month later after the 2nd dose of PRP-T and 14.65 ${\mu}g/mL$(95% CI; 10.83~19.81) at 1 month later after the 3rd dose. Anti-PRP antibody ${\geq}0.15$ ${\mu}g/mL$, was observed in 98.4%(95% CI; 91.8~100) after 2 doses and 100%(95% CI; 100~100) after 3 doses. Anti-PRP antibody ${\geq}1.0$ ${\mu}g/mL$, was obtained in 77.8%(95% CI; 67.5~88.0) after 2 doses, and 98.4%(95% CI; 95.3~100) after 3 doses. Most of the adverse reaction after vaccination were mild. Irritability, the most common systemic reaction, was observed in 45.5%, followed by drowsiness(30.5%), poor feeding(26.7%) and fever(5.6%). Among the local reactions tenderness was observed in 7.9%, redness(${\geq}5$ mm) in 2.8% and swelling(${\geq}5$ mm) in 1.8%. Conclusion : The PRP-T vaccine used in this study was highly immunogenic and safe in Korean young infants. The finding that high GMT and high frequency of infants with a protective titer achieved after 2 doses is consistent with the previous studies which were done with a PRP-T vaccine of other manufacturer. This study suggests that the immunization schedule of PRP-T vaccine for Korean infants may need re-evaluation.

• ANNALS OF ANIMAL RESOURCE SCIENCES
• /
• 제28권2호
• /
• pp.78-96
• /
• 2017

Foot-and-mouth disease (FMD) is a infection that can easily spread when it occurs and causes serious economic damage because of the existence of multiple serotypes of the virus and extreme contagiousness. The most effective method in preventing the transmission of FMD virus (FMDV) is the culling of livestock and additional vaccination in the other areas depending on the spreading rate and situation. Diagnostic methods are utilized not only for the definite diagnosis of FMD but also for identification of serotype, and confirmation of antibody production after vaccination. Although many methods have been developed to diagnose, they are not still enough to detect accurately the disease in a short time. Therefore, it has been needed new diagnostic methods improved from existing methods. Previous methods were based on the enzyme-linked immunosorbent assay (ELISA) as a serological diagnostic method, or polymerase chain reaction (PCR), which is a molecular genetic method. The recent technology has been performing about the combination of both methods and how to make it faster, less costly, more sensitive and accurate way.

• Clinical and Experimental Pediatrics
• /
• 제46권9호
• /
• pp.846-853
• /
• 2003

Purpose : Pneumoccocus is one of the most important causes of invasive infection through the childhood period and the prevelance of antibiotics resistance of pneumococcus is increasing worldwide. A 7-valent conjugate vaccine has been developed. It is important to know the prevalence of each serotype of pneumococci in the countries where the vaccine is used to estimate the coverage rate by the vaccine. Methods : One hundred and twenty seven strains of clinical isolates and 72 strains from healthy carriers recovered from Korean children during the period from 1997 to 2002 were subjected to determination of serotype by Quellung reaction and penicillin susceptibility with oxacillin disc diffusion test. Results : Forty-three per cent of clinical isolates were obtained from children under two years of age. Thirty strains(24%) were isolated from normally sterile body fluids. The frequent serotypes were 19F, 19A, 23F, 6A, 6B and 9V. Fifty-six per cent of the clinical isolates were represented in the current 7-valent protein conjugate pneumococccal vaccine, and 84% when the cross-reactive serotypes were included. Frequent serotypes of strains isolated from one to five year-old healthy children were 19F, 14, 11A, 23F, 18C, and 19A. Seventy-one per cent of the carrier strains were included in the 7-valent vaccine. Ninety-three per cent of the clinical isolates and 86% of carrier strains were not susceptible to penicilline. Conclusion : Fifty-six to 84% of pneumococci recovered from Korean children are covered by the current 7-valent protein conjugate pneumococcal vaccine and the prevalence of penicillin resistance was very high.

• Pediatric Infection and Vaccine
• /
• 제5권2호
• /
• pp.245-257
• /
• 1998

Purpose : Although hepatitis B vaccine has been available to general population in Korea since 1983, it was difficult to compare various types of hepatitis B virus(HBV) vaccines primarily due to the differences in vaccination schedule, dosage, test methods and seropositive antibody level. In this study we reviewed the results of previous studies published in Korea, which include antibody positive rates and antibody titers of various vaccines, and examined the immunogenicity of these HBV vaccines. Methods : Studies published in medical journals, university journals concerning antibody positive rates following hepatitis B vaccination were reviewed. Inclusion criteria were those studies in which seroprotective antibody rate of 10mIU/mL or the sample ratio unit of 10 RU were used as the cut-off value and in which the test methods were RIA or ELISA. Exclusion criteria were; 1) unclear or inconsistent vaccine dosage, 2) no record of antibody titers or seroconversion rate, 3) no defined antibody rate or ratio for positive rating and 4) the vaccination schedule other than 0-1-2 months or 0-1-6 months. Results : 23 out of 52 studies were subjected for the review for seroconversion rates. 1) As for the immunogenicity in each age group, the seroconversion rates of Hepaccine(Cheil Jedang) were 85.1% in infants, 83.3% in children and 62.7% in adults, indicating higher rates in infants and children compared to adults(P<0.01). The seroconversion rates of Hepavax(Korea Green Cross) were 84.7%, 81.1% and 90.8%, indicating higher rates in infants and adults compared to children(P<0.01). 2) The seroconversion rate of Hepavax was 85.6% with 0-1-6 mo. schedule, 78.5% with 0-1-2 mo. schedule with a statistically significant difference(P<0.01). 4) There was no difference of seroconversion rates between the two doses of Hepavax, $5{\mu}g$ and $10{\mu}g$ in infants and children. 5) In adults the seroconversion rates were 62.7% with Hepaccine, 90.8% with Hepavax, and 94.8% with Engerix-B(SmithKline Beecham). Conclusion : In Korea, the incidence of chronic hepatitis B is high and changing the schedule in vaccination cannot contribute to the increase of the serocoversion rate. And in order to maximize immunogenicity, more effective vaccines as well as more proper vaccination methods should be used.

• Pediatric Infection and Vaccine
• /
• 제5권1호
• /
• pp.96-103
• /
• 1998

Purpose : We performed this study to evaluate the immune responses and protective efficacies of the HBV vaccine in infants born from hepatitis B virus(HBV) carrier mothers. Methods : Seventy eight infants born from HBV carrier mothers, who were able to follow up for 12months in the Catholic University St. Vincents hospital, were involved in this study from July 1995 to December 1996. Samples were collected at birth, 4, 8 and 12months after injection of HBIG and HBV heat-inactivated plasma derived vaccines. We evaluated the changes and relationships of viral markers detecting by enzyme immunoassay and radioimmunoassay between HBV carrier mothers and their infants. Results : 1) A total of 5.0%(106/2,117) of pregnant women were found to be a HBV carrier. The rates of HBeAg positive and negative were 38.5%(37/96) and 61.5%(59/96), respectively. 2) The seroconversion rates of anti-HBs with infants of HBV carrier mothers at 4, 8 and 12 months were 85.9%(67/78), 75.6%(59/78) and 73.1%(57/78), respectively. Although these were statistically significant differences(P<0.05), they were not related to HBeAg status of the mothers. The geometric mean titers of anti-HBs at 8 and 12 months were significantly higher than at 4 months, statistically(P<0.05). The protective efficacy of the HBV vaccine and HBIG at 12 months in infants from HBeAg positive and negative mothers were 89.8% and 100%, respectively. 3) Five of 78(6.4%) infants became infected by HBV from only HBeAg positive mothers during the follow up period of 12 months. Three of 5 infected infants became HBV carriers. HBsAg positive at birth from HBeAg positive and negative mother were 4 infants, respectively. Three of 4 infants became infected by HBV from only HBeAg positive mothers. Conclusion : We confirmed that the seroconversion rate of HBV heat-inactivated plasma derived vaccine which was one of other vaccines manufacturing in Korea was 85.9%. The protective efficacy of this HBV vaccine and HBIG at 12 months in infants from HBeAg positive and negative mothers were 89.8% and 100%, respectively.

• Journal of the korean veterinary medical association
• /
• 제32권4호
• /
• pp.234-246
• /
• 1996

양의 스크래피(scrapie)는 우리나라에서의 발생보고가 없는 해외가축전염병의 일종이며, 동물의 전염성 해면형 뇌증(Transmissible Spomgifrom Encephalopathies; TSEs)중 역사가 가장 오랜 질병인데, 현재 영국에서 문제되고 있는 새로운 전염병인 소 해면형 뇌증(Bovine Spongiform Encephalopathy; BSE) 즉 일명 광우병(mad cow disease)과의 어떤 연관 가능성 때문에 수의학계의 관심의 대상이 되고 있는 질병이다. 일단 감염되어 발병되면 치료대책 없이 100$\%$ 폐사되는 세기의 불치병으로 알려진, 소 해면형 뇌증(BSE)은 영국에서 현재 사람의 크로이츠휄트-야콥병(Creutzfeldt-Jakob disease; CJD)과의 관련 가능성 여부를 놓고 독특한 문제가 되고 있는 세계적인 희귀질병이다. 이들 질병에 대하여는 아직까지 확실한 병인체가 밝혀져 있지도 않으며, 그렇기 때문에 면역 혈청학적 진단방법도 확립되어 있지 못할 뿐만아니라 예방백신의 개발 또한 불가능하다. 다만, 임상적인 병력과 임상소견, 뇌조직 표본에 대한 현미경 검사 또는 전자현미경 검사에 의한 특이소견 관찰 등 조직병리학적 진단만이 가능할 뿐이다. 본편에서는 소 해면형 뇌증(BSE)의 병리학적 감별진단과 관련, 지금까지 보고된 임상증상을 검토해보고, 우리나라에서 경험한 소의 광견병에 대한 조직병리학적 진단 재료를 근거로하여 감별진단을 위한 참고자료로 설명하고, 국제수역사무국(Office de International Epizooties; O.I.E.)에서 발생한 Manual of Standards for Diagnostic Tests and Vaccines for List A and B Diseases of Mammals, Birds and Bees(1992)(포유류, 조류, 꿀벌에 있어서의 A급 및 B급 질병에 대한 진단시약 및 예방백신에 대한 표준지침) 중에서 소 해면형 뇌증(B 83; p 742-747)과 스크래피(B 32; p 424-427)에 관한 내용 (Chapter 22, 205-215)을 기본자료로 제공하고자 한다.

• Journal of the korean veterinary medical association
• /
• 제35권10호
• /
• pp.841-845
• /
• 1999

세계 선진 수의 기생충학회 (World Association for the Advancement of Veterinary Parasitology; (W.A.A.V.P.) 제17차 국제학술대회 (the 17th International Conference)가 1999년 8월 15일부터 20일까지, 덴마크의 대학도시 코펜하겐 (Copenhagen, Denmark)에서 개최되었다. 제17차 금년도 W.A.A.V.P 국제학술대회의 특징은, '기생충 (parasites). 생산 (production) 그리고 환경 (environment)'이라는 슬로우건을 내걸고, 06개국의 회원국에서, 750 여명이 참가하여, 13가지의 주제별로, 700여 제목의 특강과 학술발표 (구두 및 포스타 발표), 워크샵 등으로 이루어 졌다는 점이다. 새롭고 눈에 띄는 발표중에는, 네오스포라 캐나이눔 (Neosporacaninum)의 백신개발에 관한 연구보고도 있었다, 금년도 W.A.A.V.P. 국제학술대회에는 우리나라에서 필자를 포함하여 서울대학교 수의과대학 기생충학 교실에서 윤희정 교수와, 박사학위 과정중에 있는 이종경 수의사와 서흔수 수의사가 참여하었으며 3 제목을 발표하었다. 앞으로, 2년 후에는, 제18차 W.A.A.V.P. 국제학술대회가 이태리의 스트레사라는 도시에서, '전진을 가속화, 전통을 지키며' ('Promoting Advancement, Preserving Tradition')이라는 슬로우건을 내걸고 열리게 될 예정이다. 우리나라 수의기생충 연구업무의 활성화 위하여, 세계 선진 수의 기생충학회 제17차 코펜하겐 학술대회와 제18차 스트레사 학술대회에 관한 정보를 제공하고자 한다.

• KSBB Journal
• /
• 제26권6호
• /
• pp.491-504
• /
• 2011

This review article provides an overview of the evolution of diphtheria vaccine, its value and its future. Diphtheria is an infectious illness caused by diphtheria toxin produced by pathogenic strains of Corynebacterium diphtheriae. It is characterized by a sore throat with membrane formation due to local tissue necrosis, which can lead to fatal airway obstruction; neural and cardiac damage are other common complications. Diphtheria vaccine was first brought to market in the 1920s, following the discovery that diphtheria toxin can be detoxified using formalin. However, conventional formalin-inactivated toxoid vaccines have some fundamental limitations. Innovative technologies and approaches with the potential to overcome these limitations are discussed in this paper. These include genetic inactivation of diphtheria toxoid, innovative vaccine delivery systems, new adjuvants (both TLR-independent and TLR-dependent adjuvants), and heat- and freeze-stable agents, as well as novel platforms for producing improved conventional vaccine, DNA vaccine, transcutaneous (microneedle-mediated) vaccine, oral vaccine and edible vaccine expressed in transgenic plants. These innovations target improvements in vaccine quality (efficacy, safety, stability and consistency), ease of use and/or thermal stability. Their successful development and use should help to increase global diphtheria vaccine coverage.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 한국응용약물학회 1993년도 제2회 신약개발 연구발표회 초록집
• /
• pp.144-144
• /
• 1993

한국에서 유행하는 페염균 type을 결정하기 위한 기초 실험을 수행하여 서울대병원과 서울중앙병원의 환자로부터 분리한 88개의 폐염균주를 담즙산에 의한 용해도 및 Optochin에 대한 민감성 등을 측정하고 폐염균의 type을 결정하기 위해서 Double diffusion, Countercurrent immunoelectrophoresis, Rocket immunoelectrophoresis 방법 등으로 폐염균 항혈청과 반응하였다. 또한 ATCC로부터 구입한 폐염균주를 이용하여 배지조성의 변화에 따른 폐염균 생장을 측정하기 위해 CAT broth, Brain Heart Infusion broth, Defined Media에서 3가지 type의 균주(Type I, III, IV)를 접종하고 37$^{\circ}C$에서 배양하면서 1시간마다 550nm에서 흡광도를 측정하였다. 3가지 type (Type I, III, IV)의 폐염균주로부터 협막다당류를 phenol Iysis 추출법으로 폐염균 Capsule 다당류의 분리하여 Total Sugar 함량, Uronic acid 함량, 0-Acetyl 함량, 단백질 함량, 핵산 함량, 분자량분포 Countr-current immunoelectrophoresis 등을 실시하여 폐염균 백신 규격에 부합되는지 확인하였다. 수집한 88개의 폐염균주가 모두 담즙산에 의해 용해되고 6mm Optochin disc를 사용하였을때 성장 저지원이 모두 14mm 이상으로 나타나 감수성이 있어서 폐염균임을 확인하였으며 폐염균의 type 결정에 필요한 방법을 설정하였다. 배지조성에 따른 폐염균의 생장을 측정한 결과 CAT broth 에서는 Type I만이 잘 배양되었고 Type III, IV는 늦게 배양되었으나, Brain Heart Infusion broth에서는 3가지 Type이 모두 잘 배양되었고, Defined Media 에서는 Type I만이 성장되었을 뿐 나머지 두 Type은 배양되지 않았다. 본 실험방법으로 분리된 폐염균 다당류는 폐염균 백신 규격중의 6가지 항목에서 적합하였으며 Statens(Denmark)로부터 구입한 항체와 뚜렷한 침강선을 나타내었다.

• Proceedings of the Korea Concrete Institute Conference
• /
• 한국콘크리트학회 1992년도 가을 학술발표회 논문집
• /
• pp.119-124
• /
• 1992

최근들어 고속도로, 고속철도,지하철 등의 건설이 급격히 증가함에 따라 터널의 건설이 늘어나고 있다. 이러한 터널등의 건설에서 필수적으로 따르는 것이 숏크리트의 시공이며 이러한 숏크리트의 시공은 앞으로 더욱 증가할 추세에 있다. 그러나 숏크리트의 광범위한 시공에도 불구하고 현재 여러 가지 문제점을 내포하고 있는 것이 사실이다. 따라서 본 연구에서는 우리나라 현행 숏크리트의 현황과 문제점을 도출하여 성능개선을 위한 최적 배합을 도출하고 고품질의 숏크리트 시공을 위하여 실리카퓸 숏크리트의 개발 및 적용과 인성(Toughness)과 연성(Ductility)을 대폭 증가시키고 시공속도를 빠르게 하여 안전성과 함께 경제성을 확보할 수 있는 강섬유보강 숏크리트의 개발 및 적용에 대한 연구를 집중적을 수행하였다. 본 연구로부터 숏크리트의 최적 배합을 도출하였고 강도와 내구성을 함께 증가시키고 리바운드율을 대폭 감소시킬 수 있는 실리카퓸 숏크리트를 개발하였다. 또한 wiremesh를 대체할 수 있는 강섬유보강 숏크리트를 개발하여 실내시험 및 현장 적용성 시험을 수행하였다.